搏动性体外心室辅助装置在99例新生儿、婴儿及儿童中的100次支持经验
该单中心回顾性研究分析了99例接受搏动性体外心室辅助装置(Berlin Heart)支持的患儿(共100次支持),其中47例体重<5 kg。主要不良预后风险因素包括先天性心脏病(CHD)、肝功能障碍和出血,而双心室心脏及双心室辅助装置支持为保护因素。总体1年和5年生存率分别为74.5%和69.8%,体重<5 kg患儿分别为63.4%和60.9%。
要点
- CHD、肝功能障碍和出血是搏动性VAD患儿死亡的独立风险因素。
- 双心室心脏及双心室辅助装置支持与更好的生存相关。
- 体重<5 kg、CHD及功能性单心室循环患儿生存率更低。
核心结论
- 搏动性VAD可为新生儿、婴儿及儿童提供桥接至移植,但小体重、CHD及功能性单心室循环患儿生存更差。
研究设计与样本
- 单中心回顾性研究,纳入99例接受100次搏动性体外心室辅助装置(Berlin Heart)支持的患儿,其中47例体重<5 kg。
主要发现
- CHD(HR 2.25;95% CI 1.22-4.13;P=.009)、肝功能障碍(HR 3.46;95% CI 1.56-7.69;P=.002)和出血(HR 3.91;95% CI 1.87-8.18;P=.0002)是死亡风险因素。
- 双心室心脏(HR 0.38;95% CI 0.18-0.8;P=.01)和双心室辅助装置支持(HR 0.35;95% CI 0.16-0.76;P=.007)为保护因素。
- 全部99例患儿1年和5年生存率分别为74.5%(95% CI 66.4%-83.7%)和69.8%(95% CI 61.1%-79.7%)。
- 47例体重<5 kg患儿1年和5年生存率分别为63.4%(95% CI 50.9%-78.9%)和60.9%(95% CI 48.3%-76.9%)。
- 获得性心脏病较CHD(log-rank P=.003)、双心室较单心室循环(log-rank P=.026)长期生存更优。
临床怎么用
- 对CHD、肝功能障碍或出血的患儿启动搏动性VAD支持时,应充分评估高风险并加强管理。
- 体重<5 kg及功能性单心室循环患儿预后较差,需个体化决策及密切随访。
局限性
- 单中心回顾性研究,结果外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Unique challenges exist with providing ventricular assist device (VAD) support to neonates, infants, and children with congenital heart disease (CHD), functionally univentricular circulation, and those weighing <5 kg. We review our experience with all patients ever supported with Berlin Heart at University of Florida and assess risk factors for mortality and outcomes in high-risk subgroups. METHODS: Overall outcomes of 99 patients who underwent 100 separate episodes of support with Berlin Heart were assessed; 47 patients weighed <5 kg. Patients with CHD (n =53) were compared with those with acquired heart disease (n = 45), and patients with functionally univentricular circulation (n = 40) were compared with those with biventricular circulation (n = 59). The primary outcome was mortality. Survival was modeled by the Kaplan-Meier method. Univariable Cox proportional hazard models identified prognostic factors for survival. Kaplan-Meier methods and log-rank tests were used to assess group differences in long-term survival. RESULTS: Risk factors for mortality were CHD (hazard ratio [HR], 2.25; 95% CI, 1.22-4.13; P = .009), liver dysfunction (HR, 3.46; 95% CI, 1.56-7.69; P = .002), and bleeding (HR, 3.91; 95% CI, 1.87-8.18; P = .0002). Biventricular heart (HR, 0.38; 95% CI, 0.18-0.8; P = .01) and biventricular assist device support (HR, 0.35; 95% CI, 0.16-0.76; P = .007) were protective. Overall survival at 1 and 5 years in all 99 patients was 74.5% (95% CI, 66.4%-83.7%) and 69.8% (95% CI, 61.1%-79.7%). Survival at 1 and 5 years in all 47 patients <5 kg was 63.4% (95% CI, 50.9%-78.9%) and 60.9% (95% CI, 48.3%-76.9%). Longitudinal survival is better in acquired heart disease vs CHD (log-rank P = .003) and biventricular vs univentricular patients (log-rank P = .026). CONCLUSIONS: Pulsatile VAD facilitates bridge to transplantation in neonates, infants, and children; however, survival is worse in smaller patients, those with CHD, and those with functionally univentricular circulation. These challenging subgroups represent important opportunities for improvement.
引用
- Bleiweis MS, Philip J, Fudge JC, et al. 100 Episodes of Support With Pulsatile Paracorporeal Ventricular Assist Device in 99 Neonates, Infants, and Children At a Single Institution. Ann Thorac Surg. 2025. PMID: 40789499. doi:10.1016/j.athoracsur.2025.07.022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。